• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for Irish Healthcare Professionals only

      One dose, one tablet,
      once a day1

      Once-daily oral treatment for your adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)1


      1. RINVOQ (upadacitinib) Summary of Product Characteristics, available at www.medicines.ie. 

      Date of preparation: June 2020  IE-RNQR-200012

      RINVOQ HUMIRA – Legal Category: POM (S1A).
      Further information is available on request from AbbVie Limited, 14 Riverwalk, Citywest Business Campus, Dublin 24, Ireland.


      ▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie